Want to see HK:6855 full AI Analyst Report?
6855 Stock Chart & Stats
HK$50.90
-HK$0.65(-1.60%)
At close: 4:00 PM EST
HK$50.90
-HK$0.65(-1.60%)
Day’s Range― - ―
52-Week RangeHK$30.00 - HK$83.15
Previous CloseN/A
Volume1.20M
Average Volume (3M)2.91M
Market Cap
HK$12.97B
Enterprise ValueHK$12.63K
Total Cash (Recent Filing)HK$1.90B
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Mar 31, 2027EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.89
Shares Outstanding373,616,240
10 Day Avg. Volume3,624,329
30 Day Avg. Volume2,906,439
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.61
Price to Sales (P/S)29.89
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$44.37Price Target Upside-12.84% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.96
Revenue Forecast (FY)HK$826.98M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid revenue expansion indicates improving commercial traction and growing demand for the company’s oncology-focused pipeline. If sustained, stronger top-line scale can support future operating leverage as products advance and commercialization capabilities develop.
High Gross MarginsHigh gross margins are consistent with the economics of innovative biotech products and licensing activities. They suggest that successful commercialization or partnerships could generate substantial contribution margins, although operating expenses currently outweigh this benefit.
Improved Balance-Sheet LeverageThe sharp reduction in debt-to-equity and stronger equity base improve financial flexibility compared with prior years. This may help the company fund clinical development and partnerships with less balance-sheet strain, though continued losses remain a risk.
Bears Say
Deep And Worsening LossesPersistent and worsening losses show that revenue growth has not yet translated into an economically sustainable business. Continued high research, development and commercial expenses could delay breakeven and increase the need for additional capital.
Intensifying Cash BurnThe sharp deterioration in operating and free cash flow increases dependence on external funding, partnerships or equity issuance. Sustained cash consumption could constrain clinical execution, weaken negotiating power and create ongoing financing or dilution risk.
Negative Returns And Funding RiskA deeply negative return on equity indicates that the enlarged capital base is not yet producing positive returns. Unless clinical progress and commercialization improve profitability, shareholders may face further dilution as the company funds operations.
Ascentage Pharma Group International News
6855 FAQ
What was Ascentage Pharma Group International’s price range in the past 12 months?
Ascentage Pharma Group International lowest stock price was HK$30.00 and its highest was HK$83.15 in the past 12 months.
What is Ascentage Pharma Group International’s market cap?
Ascentage Pharma Group International’s market cap is HK$12.97B.
When is Ascentage Pharma Group International’s upcoming earnings report date?
Ascentage Pharma Group International’s upcoming earnings report date is Mar 31, 2027 which is in 204 days.
How were Ascentage Pharma Group International’s earnings last quarter?
Ascentage Pharma Group International released its earnings results on Aug 19, 2026. The company reported -HK$2.514 earnings per share for the quarter, missing the consensus estimate of -HK$0.6 by -HK$1.913.
Is Ascentage Pharma Group International overvalued?
According to Wall Street analysts Ascentage Pharma Group International’s price is currently Overvalued.
Does Ascentage Pharma Group International pay dividends?
Ascentage Pharma Group International does not currently pay dividends.
What is Ascentage Pharma Group International’s EPS estimate?
Ascentage Pharma Group International’s EPS estimate is -0.64.
How many shares outstanding does Ascentage Pharma Group International have?
Ascentage Pharma Group International has 373,616,240 shares outstanding.
What happened to Ascentage Pharma Group International’s price movement after its last earnings report?
Ascentage Pharma Group International reported an EPS of -HK$2.514 in its last earnings report, missing expectations of -HK$0.6. Following the earnings report the stock price went down -0.572%.
Which hedge fund is a major shareholder of Ascentage Pharma Group International?
Currently, no hedge funds are holding shares in HK:6855
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascentage Pharma Group International Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ascentage Pharma Group International
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are concentrated across the United States and Mainland China. Ascentage Pharma's flagship therapeutic candidate, HQP1351 (Olverembatinib), is a BCR-ABL inhibitor specifically designed to target BCR-ABL mutants, including those carrying the T315I mutation. This compound is intended for patients suffering from chronic phase chronic myeloid leukemia that has become resistant to tyrosine kinase inhibitors. Beyond HQP1351, the company boasts a robust pipeline. This includes APG-2575 (Pelcitoclax), an orally administered, selective Bcl-2 inhibitor undergoing Phase Ib/II clinical studies for hematologic and solid tumors; APG-115 (Alrizomadlin), an oral small molecule designed to inhibit the MDM2-p53 protein-protein interaction for various solid and hematological malignancies; and APG-1387 (Nevadotinib), a small molecule inhibitor of apoptosis proteins targeting advanced solid tumors and chronic HBV infections. Further advancing its portfolio, Ascentage is developing APG-1252 (Atoloclab), a small molecule drug aimed at restoring apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins for conditions such as small cell lung cancer (SCLC), lymphoma, and other solid tumors. The pipeline also features APG-2449 (Glecirasib) for non-small-cell lung carcinoma (NSCLC); APG-5918, an orally available and selective EED inhibitor with best-in-class potential in its preclinical phase; APG-265, currently in IND-enabling stages for hematological and solid tumors; and UBX1967/1325, a Phase II candidate targeting the Bcl family for diabetic macular edema (DME). The company maintains strategic collaboration agreements with prominent biotechnology and pharmaceutical companies, as well as academic institutions. Key partners include Innovent Biologics, Inc., the National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. Established in 2009, Ascentage Pharma is headquartered in Suzhou, China.
6855 Stock 12 Month Forecast
Average Price Target
HK$44.37
▼(-12.84% Downside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Everest Medicines Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―